glp 1 and norethindrone AUROVELA (norethindrone acetate/ethinyl estradiol) GLP-1 Medications: Everything You Need

PlexusDx explores the safety, interactions, and personalized approach to using both medications for weight management and mood support

Electronic databases including PubMed, Embase, and Web of Science were searched from inception until August 2025 using keywords such as GLP-1 receptor agonist, diabetic retinopathy, glaucoma, age-related macular degeneration, ocular disease, and neuroprotection. The search focused on identifying preclinical studies, large-scale retrospective cohort studies, and post-hoc analyses of major clinical trials that evaluated the utility and potential mechanisms of GLP-1RAs in ophthalmic diseases

A large Cleveland Clinic study has found that people with obesity and Type 2 diabetes who undergo weight-loss surgery live longer and face fewer serious health problems compared with those treated with GLP-1 receptor agonist medicines alone.

PlexusDx explains the interaction profile, safety considerations, and how personalized genetic testing informs dual-therapy decisions

Genetically-predicted GLP1R expression (the target of GLP-1 RAs) showed an inverse association with background [odds ratio (OR)=0.83, 95% CI, 0.710.97] and severe nonproliferative DR (OR=0.72, 95% CI, 0.530.98), and a non-significant association with overall (OR=0.97, 95% CI, 0.921.03) and proliferative DR (OR=0.98, 95% CI, 0.911.05)